PubMed · 2002 · 98 citations · 19 references
PharmacyOphthalmologyPharmaceuticsDrug DeliveryOcular Drug DeliveryOphthalmic Drug DeliveryLiposome-based DeliveryOcular NanocarriersOcular Targeted DeliveryOligonucleotide DeliveryOphthalmic FormulationsVitreous Drug DeliveryDrug Delivery To The ChoroidDrug Delivery To The VitreousDrug Transport Across Ocular TissuesIntravitreal BioavailabilityLiposomal Delivery SystemsOcular Tissue DistributionOligonucleotide TherapeuticsPhosphodiester Oligonucleotides
PURPOSE: The efficacy of sterically stabilized liposomes for delivering a model phosphodiester oligonucleotide intravitreally was investigated in the rabbit. METHODS: Ocular distribution and clearance from the vitreous humor of a model 16-mer oligothymidylate (pdT16) were evaluated in the rabbit by radioactivity measurements after intravitreal injection of either a solution or liposomes containing the [33P]pdT16 oligonucleotide. The integrity of pdT16 was investigated using a competitive hybridization assay. RESULTS: The residual concentration of the [33P]pdT16 oligonucleotide within the ocular tissues was significantly increased after intravitreal administration of the liposomal suspension compared with a simple solution. Administration of liposome-encapsulated pdT16 oligonucleotide resulted in sustained release into the vitreous and the retina-choroid compared with release from the solution and in a reduced distribution to nontarget tissues (sclera, lens). In addition, liposomes protected the phosphodiester oligonucleotide against degradation. This was not observed after administration of the free oligonucleotide. CONCLUSIONS: The intravitreal injection of a phosphodiester oligonucleotide encapsulated within liposomes is a new way of delivering intact oligonucleotide to the eye in a controlled manner. This offers interesting prospects for the treatment of retinal diseases.
19
Francis C. Szoka, Fred C. Olson, Timothy D. Heath et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 1980 · 474 citations